Clinical trials: Glabellar Lines
Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
- Trial name
- NCT03786770
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
- Trial name
- NCT05321979
- Testing
- MBA-P01
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Medytox Korea
Glabellar Lines
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Hyperfunctional facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05013424
- Testing
- Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- Allergan
Glabellar Lines
Study of DWP450 in Japanese Subjects With Glabellar Lines
Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07783763
- Testing
- DWP450 20 U, 0.9% Saline Solution 0.5 mL
- Volunteers
- 120 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03736928
- Testing
- AbobotulinumtoxinA dose level 1 or 2, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
- Where
- 10 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Rhytides
Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03a (NCT00752297)
- Testing
- Preservative-free Saline, Mentor Purified Toxin
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Mentor Worldwide, LLC
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Lines
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
- Trial name
- NCT04096326
- Testing
- AGN-151586
- Where
- 9 sites in United States
- Volunteers
- 198 people
- Sponsor
- Allergan
Glabellar Lines
Phase 2 of HU-045 in Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT05298449
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Huons Co., Ltd.
Glabellar Frown Lines
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06585696
- Testing
- CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX®
- Where
- China
- Volunteers
- 554 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Lines
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06308198
- Testing
- AGN-151586
- Where
- 12 sites in China, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Injection Site Discomfort
A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.
- Trial name
- NCT06161246
- Testing
- Vibrating Beauty Bar
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Glabellar Frown Lines
Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines
This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.
- Trial name
- NCT02303002
- Testing
- Botulinum Toxin Type A, Active Comparator botulinum toxin
- Where
- Canada
- Volunteers
- 268 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase Ⅲ clinical trials. In Phase Ⅲ, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a…
- Trial name
- NCT05364580
- Testing
- PROTOXIN, Botox®
- Where
- 5 sites in South Korea
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Rhytides, Frown Lines Between the Eyebrows
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of repeat treatment of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03b (NCT00752050)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
- Where
- United States
- Volunteers
- 699 people
- Sponsor
- Mentor Worldwide, LLC
Facial Rhytides, Crow's Feet Lines
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE®…
- Conditions
- Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Nasolabial Fold
- Trial name
- NCT02176356
- Testing
- onabotulinumtoxinA, bimatoprost ophthalmic solution 0.03%, JUVÉDERM® ULTRA XC
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Allergan
Moderate to Severe Glabellar Lines
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines.
- Trial name
- NCT06583486
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 488 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Lines
A Study Of BOTOX For The Treatment Of Glabellar Lines
This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients with glabellar lines.
- Trial name
- NCT00408785
- Testing
- Botulinum Toxin Type A, sodium chloride
- Where
- 4 sites in China
- Volunteers
- 256 people
- Sponsor
- GlaxoSmithKline